Notice to Clarify Issues Regarding the Format and Other Special Features of the Applications for DA-08-020, Facilitating Self-Control of Substance Abuse Related Brain Activity Through Real-Time Monitoring of fMRI Signals (R21/R33)

Notice Number: NOT-DA-08-011

Key Dates
Release Date:  January 28, 2008

Issued by
National Institute on Drug Abuse (NIDA), (

This Notice is being issued to clarify issues regarding the format and other special features of the applications for RFA DA-08-020 (  The following text should be considered as part of Section IV.6 "Other Submission Requirements" in the FOA.

All application instructions outlined in the SF424 (R&R) Application Guide are to be followed, incorporating "Just-in-Time" information concepts and with the following requirements for R21/R33 applications:

Specific Instructions for Preparing a Combined R21/R33 Phased Innovation Award Application
    * The R21/R33 Phased Innovation Award application must be submitted as a single application with one Research and Related Budget component (with a detailed budget for each year of the R21 phase and the R33 phase).

    * The NIH modular budget concept is not to be used for this FOA. Even though the budget for the R21 phase is limited, applications must present the detailed SF424 (R&R) Budget forms for all years. In the budget justification, it must be indicated whether the budget year is for the R21 or the R33 phase.  The SF424 (R&R) application submitted in response to this FOA cannot be accepted with a modular budget for the R21 phase and a detailed budget for the R33 phase.

    * The total length of the Research Plan attachments section, Items 2-5 (Specific Aims, Background and Significance, Preliminary Studies, Research Design and Methods), cannot exceed 25 pages including the Milestones section.      * In preparing the R21/R33 application investigators should consider that the application will be assigned a single priority score. Thus, clarity and completeness of the application with regard to specific goals and the feasibility of each phase and the milestones are critical. Milestones that are not sufficiently scientifically rigorous to be valid for assessing progress in the R21 phase will reflect poorly on the scientific merit of the application as a whole.

Warning: Please be sure that you observe the direct cost, project period, and page number limitations specified above for this FOA. Application processing may be delayed or the application may be rejected if it does not comply with these requirements.


James Bjork, Ph.D.
Clinical Neuroscience Branch
Division of Clinical Neuroscience and Behavioral Research
6001 Executive Blvd, Rm.3151
Bethesda, MD 20892-9593
Ph: 301-443-4877
Fax: 301-443-6814

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.